{
    "guideline_id": "2024CSCO神经内分泌肿瘤诊疗指南.txt",
    "cancer_info": {
        "cancer_name": "Neuroendocrine Tumors (NENs)"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Pathological diagnosis of NENs",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "Grading based on mitotic count and Ki67 index; immunohistochemistry required: Syn, CgA, Ki67, SSTR2A; for pancreatic NETs, add DAXX/ATRX/MEN1 to detect loss indicating NET.",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "Ki67",
                    "status": "",
                    "testing_guidance": "Assess in hotspot area with ≥500 cells"
                },
                {
                    "biomarker_name": "Syn",
                    "status": "",
                    "testing_guidance": "Required for all cases"
                },
                {
                    "biomarker_name": "CgA",
                    "status": "",
                    "testing_guidance": "Required for all cases"
                },
                {
                    "biomarker_name": "SSTR2A",
                    "status": "",
                    "testing_guidance": "Required for all cases"
                },
                {
                    "biomarker_name": "DAXX",
                    "status": "",
                    "testing_guidance": "For pancreatic NETs, loss suggests NET"
                },
                {
                    "biomarker_name": "ATRX",
                    "status": "",
                    "testing_guidance": "For pancreatic NETs, loss suggests NET"
                },
                {
                    "biomarker_name": "MEN1",
                    "status": "",
                    "testing_guidance": "For pancreatic NETs, loss suggests NET"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Imaging localization for NENs",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "First choice: multiphase enhanced CT or MRI; functional imaging: 68Ga-SSA PET for NET G1-G2, 18F-FDG PET/CT for NEC or G3 NET or rapidly progressing tumors; ultrasound endoscopy (EUS) for gastrointestinal or pancreatic tumors to assess depth and lymph node involvement.",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Diagnosis of functional NENs",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "Carcinoid syndrome: 24-hour urinary 5-HIAA (avoid interfering foods); Insulinoma: 72-hour fasting test (glucose <2.8 mmol/L and insulin ≥18 pmol/L); Gastrinoma: fasting gastrin >10x upper normal limit and gastric pH <2; Ectopic ACTH syndrome: midnight salivary cortisol and dexamethasone suppression test.",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "5-HIAA",
                    "status": "",
                    "testing_guidance": "24-hour urine collection"
                },
                {
                    "biomarker_name": "Insulin",
                    "status": "",
                    "testing_guidance": "Measured during fasting test"
                },
                {
                    "biomarker_name": "Gastrin",
                    "status": "",
                    "testing_guidance": "Fasting levels"
                },
                {
                    "biomarker_name": "Cortisol",
                    "status": "",
                    "testing_guidance": "For ACTH syndrome assessment"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Treatment for non-metastatic NENs",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Surgery as primary treatment: pancreatic NETs ≤2 cm observe or local resection, >2 cm or node metastasis radical resection; gastric NETs type 1 (<1 cm) endoscopic resection, type 3 or NEC radical gastrectomy with D2 lymph node dissection; small intestine NETs segmental resection with mesenteric lymph node dissection; lung/thymic NENs anatomical resection. Postoperative adjuvant: for NEC, EP/EC chemotherapy (etoposide + cisplatin/carboplatin) ± radiotherapy for high-risk cases; for NET G3, no standard, multidisciplinary team (MDT) discussion.",
            "treatment_line": "Primary and Adjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "Ki67",
                    "status": "",
                    "testing_guidance": "Guides grading and treatment selection (e.g., NEC Ki67 >55% indicates EP/EC chemotherapy)"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Local treatment for metastatic NENs",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "For liver metastasis: resection, ablation, transarterial embolization (TAE), transarterial chemoembolization (TACE), or liver transplant with strict selection; for primary tumor in small intestine, resection to prevent mesenteric complications.",
            "treatment_line": "Local",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Systemic treatment for metastatic NETs G1-G2",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line: somatostatin analogs (SSA) such as octreotide or lanreotide for slowly progressing tumors; Second-line: targeted drugs (everolimus, surufatinib, cabozantinib), peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE, or CAPTEM regimen (capecitabine + temozolomide).",
            "treatment_line": "First-line for SSA, Second-line for others",
            "biomarker_requirements": [
                {
                    "biomarker_name": "SSTR",
                    "status": "Positive",
                    "testing_guidance": "Required for SSA and PRRT eligibility"
                },
                {
                    "biomarker_name": "MGMT",
                    "status": "",
                    "testing_guidance": "Methylation status predicts temozolomide efficacy in CAPTEM"
                }
            ],
            "recommendation_level": "Level I Recommendation for first-line SSA",
            "evidence_level": "Evidence 1A for first-line SSA"
        },
        {
            "clinical_context": "Systemic treatment for metastatic NECs",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "First-line: EP or EC chemotherapy (etoposide + cisplatin/carboplatin); Second-line: FOLFOX, topotecan, or immunotherapy (pembrolizumab for dMMR/MSI-H tumors).",
            "treatment_line": "First-line and Second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "dMMR/MSI-H",
                    "status": "Positive",
                    "testing_guidance": "Required for pembrolizumab immunotherapy in second-line"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Symptom control for functional NENs",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Carcinoid syndrome: SSA followed by telotristat ethyl (tryptophan hydroxylase inhibitor); Gastrinoma: high-dose proton pump inhibitors (PPI); Insulinoma: dietary modification and diazoxide (avoid SSA to prevent hypoglycemia).",
            "treatment_line": "Symptomatic",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Ki67 index guides tumor grading and chemotherapy selection (e.g., NEC Ki67 >55% favors EP/EC); SSTR expression indicates suitability for somatostatin analogs or peptide receptor radionuclide therapy; MGMT methylation predicts response to temozolomide; SDHB loss suggests high metastasis risk in paragangliomas/pheochromocytomas; genetic mutations (e.g., MEN1, RET, VHL, SDHx) require screening for hereditary syndromes."
    },
    "tcm_recommendations": []
}